363 related articles for article (PubMed ID: 15851013)
1. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
2. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
3. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
4. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
5. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
8. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
9. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
10. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
11. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
12. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
13. Aspartoacylase gene knockout in the mouse: impact on reproduction.
Surendran S; Szucs S; Tyring SK; Matalon R
Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
[TBL] [Abstract][Full Text] [Related]
14. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
16. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
17. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
[TBL] [Abstract][Full Text] [Related]
18. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
19. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to AAV in a phase I study for Canavan disease.
McPhee SW; Janson CG; Li C; Samulski RJ; Camp AS; Francis J; Shera D; Lioutermann L; Feely M; Freese A; Leone P
J Gene Med; 2006 May; 8(5):577-88. PubMed ID: 16532510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
